| pubmed-article:19162037 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19162037 | lifeskim:mentions | umls-concept:C0054594 | lld:lifeskim |
| pubmed-article:19162037 | lifeskim:mentions | umls-concept:C1522424 | lld:lifeskim |
| pubmed-article:19162037 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:19162037 | lifeskim:mentions | umls-concept:C0022116 | lld:lifeskim |
| pubmed-article:19162037 | lifeskim:mentions | umls-concept:C1514758 | lld:lifeskim |
| pubmed-article:19162037 | lifeskim:mentions | umls-concept:C0035124 | lld:lifeskim |
| pubmed-article:19162037 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:19162037 | pubmed:dateCreated | 2009-4-6 | lld:pubmed |
| pubmed-article:19162037 | pubmed:abstractText | Preventive treatment with cannabinoid agonists has been reported to reduce the infarct size in a mouse model of myocardial ischemia/reperfusion. Here we investigated the possible cardioprotective effect of selective CB(2) cannabinoid receptor activation during ischemia. We performed left coronary artery ligature in C57Bl/6 mice for 30 min, followed by 24 h of reperfusion. Five minutes before reperfusion, mice received intraperitoneal injection of the CB(2) selective agonist JWH-133 (20 mg/kg) or vehicle. Infarct size was assessed histologically and by cardiac troponin I (cTnI) ELISA. Immunohistochemical analysis of leukocyte infiltration, oxidative stress in situ quantification, real-time RT-PCR analysis of inflammatory mediators as well as western blots for kinase phosphorylation was also performed. In addition, we studied chemotaxis and integrin expression of human neutrophils in vitro. JWH-133 significantly reduced the infarct size (I/area at risk: 19.27%+/-1.91) as compared to vehicle-treated mice (31.77%+/-2.7). This was associated with a reduction of oxidative stress and neutrophil infiltration in the infarcted myocardium, whereas activation of ERK 1/2 and STAT-3 was increased. Preinjection of PI3K inhibitor LY294002, MEK 1/2 inhibitor U0126 and JAK-2 inhibitor AG-490 partially abrogated the JWH-133 mediated infarct size reduction. No changes in cardiac CXCL1, CXCL2, CCL3, TNF-alpha, and ICAM-1 expression levels were found. Furthermore, JWH-133 inhibited the TNF-alpha induced chemotaxis and integrin CD18/CD11b (Mac-1) upregulation on human neutrophils. Our data suggest that JWH-133 administration during ischemia reduces the infarct size in a mouse model of myocardial ischemia/reperfusion through a direct cardioprotective activity on cardiomyocytes and neutrophils. | lld:pubmed |
| pubmed-article:19162037 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19162037 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19162037 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19162037 | pubmed:month | May | lld:pubmed |
| pubmed-article:19162037 | pubmed:issn | 1095-8584 | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:MachFrançoisF | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:SteffensSabin... | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:BertolottoMar... | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:PelliGraziano... | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:BurgerFabienn... | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:LengletSébast... | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:MontecuccoFab... | lld:pubmed |
| pubmed-article:19162037 | pubmed:author | pubmed-author:Braunersreuth... | lld:pubmed |
| pubmed-article:19162037 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19162037 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:19162037 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19162037 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19162037 | pubmed:pagination | 612-20 | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:meshHeading | pubmed-meshheading:19162037... | lld:pubmed |
| pubmed-article:19162037 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19162037 | pubmed:articleTitle | CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. | lld:pubmed |
| pubmed-article:19162037 | pubmed:affiliation | Division of Cardiology, Foundation for Medical Researches, Department of Internal Medicine, University Hospital, Geneva, Switzerland. | lld:pubmed |
| pubmed-article:19162037 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19162037 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:12802 | entrezgene:pubmed | pubmed-article:19162037 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19162037 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19162037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19162037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19162037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19162037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19162037 | lld:pubmed |
